Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewMLS 1547 is a G protein-biased D2 receptor partial agonist (Ki = 1.2 μM). Stimulates D2 receptor G protein-mediated signaling and acts as an antagonist of dopamine-mediated β-arrestin recruitment at D2 receptors.
MLS 1547 is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.
M. Wt | 354.83 |
Formula | C19H19ClN4O |
Storage | Store at +4°C |
Purity | ≥98% (HPLC) |
CAS Number | 315698-36-3 |
PubChem ID | 1093278 |
InChI Key | OPEJNANYABTIGC-UHFFFAOYSA-N |
Smiles | OC1=C(C=C(C2=C1N=CC=C2)Cl)CN3CCN(C4=CC=CC=N4)CC3 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 35.48 | 100 |
The following data is based on the product molecular weight 354.83. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 2.82 mL | 14.09 mL | 28.18 mL |
5 mM | 0.56 mL | 2.82 mL | 5.64 mL |
10 mM | 0.28 mL | 1.41 mL | 2.82 mL |
50 mM | 0.06 mL | 0.28 mL | 0.56 mL |
References are publications that support the biological activity of the product.
Free et al (2014) Discovery and characterization of a G protein-biased agonist that inhibits β-arrestin recruitment to the D2 DA receptor. Mol.Pharmacol. 86 96 PMID: 24755247
If you know of a relevant reference for MLS 1547, please let us know.
Keywords: MLS 1547, MLS 1547 supplier, MLS1547, dopamine, D2, DA, partial, agonists, agonism, G, protein, biased, signaling, Receptors, 6171, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for MLS 1547 include:
Stefan et al (2021) New phosphosite-specific antibodies to unravel the role of GRK phosphorylation in dopamine D2 receptor regulation and signaling. Sci Rep 11 8288 PMID: 33859231
Ting et al (2021) Exploiting D2 receptor β-arrestin2-biased signalling to suppress tumour growth of pituitary adenomas. Br J Pharmacol 178 3570-3586 PMID: 33904172
Do you know of a great paper that uses MLS 1547 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review MLS 1547 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.